🏛️ Verified NIH Record • Updated 2025-08-01
Study of PYX-106 in Solid Tumors (NCT05718557)
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Pyxis Oncology, Inc
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- HonorHealth Research Institute — Scottsdale, Arizona
- University of California San Diego — La Jolla, California
- University of Southern California — Los Angeles, California
- SCRI- HealthOne Denver — Denver, Colorado
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- University of Chicago Medicine — Chicago, Illinois
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Gabrail Cancer and Research Center — Canton, Ohio
- Lifespan - Rhode Island Hospital — Providence, Rhode Island
- NEXT Oncology — Irving, Texas
- NEXT Virginia — Fairfax, Virginia
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg — Leuven, Flemish Brabant
- Grand Hôpital de Charleroi - Notre Dame — Charleroi, Hainaut
- Universitair Ziekenhuis Gent — Ghent, Oost-Vlaanderen
- Cliniques Universitaires Saint-Luc — Brussels,
- Hospital Universitari Dexeus — Barcelona, Barcelona
- START Madrid - Hospital Universitario Fundación Jiménez Díaz — Madrid, Madrid
- Hospital Universitario 12 de Octubre — Madrid, Madrid
- HM Centro Integral Oncológico Clara Campal — Madrid, Madrid
- Hospital Clínico Universitario de Valencia — Valencia, Valencia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.